MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Mostrar otras versiones (1)

Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. This article presents evidence‐based clinical practice guidelines for the management of mucositis.

Detalles Bibliográficos
Autores principales: Lalla, Rajesh V., Bowen, Joanne, Barasch, Andrei, Elting, Linda, Epstein, Joel, Keefe, Dorothy M., McGuire, Deborah B., Migliorati, Cesar, Nicolatou‐Galitis, Ourania, Peterson, Douglas E., Raber‐Durlacher, Judith E., Sonis, Stephen T., Elad, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley 2014
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164022/
https://www.ncbi.nlm.nih.gov/pubmed/24615748
http://dx.doi.org/10.1002/cncr.28592
Descripción
Sumario:Mucositis is a highly significant, and sometimes dose‐limiting, toxicity of cancer therapy. This article presents evidence‐based clinical practice guidelines for the management of mucositis.

Ejemplares similares